- Home
- DMAC vs JPI Comparison
DMAC vs JPI Comparison
Compare DMAC & JPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- JPI
- Stock Information
- Founded
- DMAC 2000
- JPI 2012
- Country
- DMAC United States
- JPI United States
- Employees
- DMAC N/A
- JPI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- JPI Finance Companies
- Sector
- DMAC Health Care
- JPI Finance
- Exchange
- DMAC Nasdaq
- JPI Nasdaq
- Market Cap
- DMAC 310.1M
- JPI 288.1M
- IPO Year
- DMAC N/A
- JPI N/A
- Fundamental
- Price
- DMAC $5.98
- JPI $20.20
- Analyst Decision
- DMAC Strong Buy
- JPI
- Analyst Count
- DMAC 3
- JPI 0
- Target Price
- DMAC $12.33
- JPI N/A
- AVG Volume (30 Days)
- DMAC 314.0K
- JPI 54.7K
- Earning Date
- DMAC 08-12-2025
- JPI 01-01-0001
- Dividend Yield
- DMAC N/A
- JPI 6.15%
- EPS Growth
- DMAC N/A
- JPI N/A
- EPS
- DMAC N/A
- JPI N/A
- Revenue
- DMAC N/A
- JPI N/A
- Revenue This Year
- DMAC N/A
- JPI N/A
- Revenue Next Year
- DMAC N/A
- JPI N/A
- P/E Ratio
- DMAC N/A
- JPI N/A
- Revenue Growth
- DMAC N/A
- JPI N/A
- 52 Week Low
- DMAC $3.19
- JPI $16.02
- 52 Week High
- DMAC $6.82
- JPI $19.12
- Technical
- Relative Strength Index (RSI)
- DMAC 65.09
- JPI 42.10
- Support Level
- DMAC $5.90
- JPI $20.00
- Resistance Level
- DMAC $6.18
- JPI $20.42
- Average True Range (ATR)
- DMAC 0.39
- JPI 0.18
- MACD
- DMAC 0.02
- JPI -0.01
- Stochastic Oscillator
- DMAC 79.10
- JPI 31.25
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.